Cancer Stem Cells in Acute Lymphoblastic Leukemia and Ovarian Carcinoma
急性淋巴细胞白血病和卵巢癌中的癌症干细胞
基本信息
- 批准号:8212933
- 负责人:
- 金额:$ 31.1万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2011
- 资助国家:美国
- 起止时间:2011-02-01 至 2013-01-31
- 项目状态:已结题
- 来源:
- 关键词:AcuteAcute Lymphocytic LeukemiaAdultAdult Acute Lymphocytic LeukemiaBindingBiologyCellsChildhoodClinicalDataDiseaseDrug resistanceEffectivenessEmbryonic DevelopmentErinaceidaeEyeGenerationsGlycosylphosphatidylinositolsGrowthGrowth FactorHematopoietic Stem Cell TransplantationHematopoietic stem cellsLymphocyteLymphoidMaintenanceMalignant NeoplasmsMalignant neoplasm of ovaryMembrane Transport ProteinsMemory B-LymphocyteMultiple MyelomaNeoplastic Plasma CellNormal tissue morphologyOutcomeOvarian CarcinomaPlasma CellsPropertyPublicationsRelapseRelative (related person)Signal PathwaySolid NeoplasmStem cellsTelomeraseTestingTherapeuticaldehyde dehydrogenasescancer cellcancer stem cellcancer therapyclinically significantimprovedleukemialeukemic stem cellnotch proteinprogenitorresponseself-renewalstem cell populationtherapeutic effectivenesstherapy developmenttherapy resistanttraittreatment effecttumor
项目摘要
Cancer stem cells have recently been identified in several different malignancies. An example is our finding
that the hallmark of multiple myeloma (MM), the neoplastic plasma cells (PC), have limited replicative
potential; rather, the MM PC actually arise from self-renewing cancer stem cells that resemble memory B
cells. Although the clinical significance of cancer stem cells remains uncertain, our preliminary data suggest
that they are responsible for many of the relapses that follow anticancer therapy. Several unrelated
malignancies, such as adult acute lymphocytic leukemia (ALL) and ovarian carcinoma, share the trait of high
initial complete clinical response rates that are usually not durable. The dramatic initial response rates in ALL
and ovarian carcinoma could represent therapeutic effectiveness against the differentiated cancer cells
making up the bulk of the tumor; the high rate of relapses could represent rare, biologically distinct cancer
stem cells resistant to the therapies effective against the tumor bulk. The development of treatments for the
cancer stem cells has been hindered by the rarity of these cells; in fact, therapies directed against targets
uniquely expressed by cancer stem cells might be prematurely abandoned if clinical activity is judged solely
by standard response criteria that reflect the effects of treatment on the bulk of the cancer. Cancer stem cells
appear to share a number of properties that distinguish normal tissue-specific stem cells from their
differentiated progeny. These shared properties include cellular quiescence, high expression of ATP binding
cassette (ABC) membrane transporters, increased levels of aldehyde dehydrogenase (ALDH) activity, and
absence of glycosyl-phosphatidylinositol (GPI) anchors. In addition, several signaling pathways that are
important for the generation and maintenance of normal stem cells during embryonic development [e.g,
Notch, Wnt, and Hedgehog (Hh)] and/or postnatally (e.g., telomerase and growth factors) also appear to be
important for the growth of many cancers. Shared stem cell properties not only likely contribute to the relative
drug resistance of cancer stem cells, but can also aid in the identification and isolation of cancer stem cells,
as well as serve as targets for new therapies that have potential effectiveness, across many cancers. The
overall objective of this project is to better understand the biology of cancer stem cells in both ALL in ovarian
carcinoma with an eye to improving therapeutic outcomes. One hypothesis to be tested is that the divergent
outcomes between pediatric-type and adult-type ALL are the result of different stem cell populations; i.e.
pediatric-type ALL arises from lymphoid progenitors while adult-type arises from hematopoietic stem cells.
Another is that specifically targeting ALL and ovarian cancer stem cells will improve the outcome of these
two diseases.
最近在几种不同的恶性肿瘤中发现了癌症干细胞。我们的发现就是一个例子
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
RICHARD J JONES其他文献
RICHARD J JONES的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('RICHARD J JONES', 18)}}的其他基金
相似海外基金
Understanding of the onset and recurrence pattern of intractable acute lymphocytic leukemia based on clone analysis
基于克隆分析了解难治性急性淋巴细胞白血病的发病和复发模式
- 批准号:
20K08723 - 财政年份:2020
- 资助金额:
$ 31.1万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Novel Inhibitors of Multi-Drug-Resistant Mutants of BCR-ABL for the Treatment of Chronic Myelogenous Leukemia (CML) and Ph Positive Acute Lymphocytic Leukemia (ALL).
BCR-ABL 多重耐药突变体的新型抑制剂,用于治疗慢性粒细胞白血病 (CML) 和 Ph 阳性急性淋巴细胞白血病 (ALL)。
- 批准号:
9047400 - 财政年份:2015
- 资助金额:
$ 31.1万 - 项目类别:
The Role of Genetic Variants in Sensitivity to Methotrexate in Acute Lymphocytic Leukemia Survivors
遗传变异在急性淋巴细胞白血病幸存者对甲氨蝶呤敏感性中的作用
- 批准号:
319114 - 财政年份:2014
- 资助金额:
$ 31.1万 - 项目类别:
Fellowship Programs
Targeting the Bone Marrow Microenvironment In Acute Lymphocytic Leukemia
针对急性淋巴细胞白血病的骨髓微环境
- 批准号:
8595788 - 财政年份:2013
- 资助金额:
$ 31.1万 - 项目类别:
Targeting hypoxic microenvironment in Acute Lymphocytic Leukemia
针对急性淋巴细胞白血病的缺氧微环境
- 批准号:
8023518 - 财政年份:2011
- 资助金额:
$ 31.1万 - 项目类别:
Targeting hypoxic microenvironment in Acute Lymphocytic Leukemia
针对急性淋巴细胞白血病的缺氧微环境
- 批准号:
8404025 - 财政年份:2011
- 资助金额:
$ 31.1万 - 项目类别:
Targeting hypoxic microenvironment in Acute Lymphocytic Leukemia
针对急性淋巴细胞白血病的缺氧微环境
- 批准号:
8220724 - 财政年份:2011
- 资助金额:
$ 31.1万 - 项目类别:
Targeting hypoxic microenvironment in Acute Lymphocytic Leukemia
针对急性淋巴细胞白血病的缺氧微环境
- 批准号:
8599754 - 财政年份:2011
- 资助金额:
$ 31.1万 - 项目类别:
INSULIN RESISTANCE IN CHILDREN WITH ACUTE LYMPHOCYTIC LEUKEMIA UNDERGOING INDUCT
正在接受治疗的急性淋巴细胞白血病儿童的胰岛素抵抗
- 批准号:
8356701 - 财政年份:2010
- 资助金额:
$ 31.1万 - 项目类别:
INSULIN RESISTANCE IN CHILDREN WITH ACUTE LYMPHOCYTIC LEUKEMIA UNDERGOING INDUCT
正在接受治疗的急性淋巴细胞白血病儿童的胰岛素抵抗
- 批准号:
8166720 - 财政年份:2009
- 资助金额:
$ 31.1万 - 项目类别:














{{item.name}}会员




